Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, T2D and other metabolic diseases.

Braskem is considering expanding its ethylene cracker and polyethylene complex in the Brazilian state of Rio de Janeiro by ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo Nordisk announced it will work with the biotech Septerna to develop oral GLP-1 obesity drugs in a deal worth up to $2.2 billion, including $200 million upfront. GSK is paying $1.2 billion upfront ...

Danish drug manufacturer Novo Nordisk is partnering with California-based biotech Septerna to develop the latest pills to treat obesity, type 2 diabetes, and other metabolic disorders. The deal could ...

Septerna's partnership with Novo Nordisk validates its GPCR drug discovery ... The stock trades below net cash even after the Novo deal, offering investors a rare opportunity to buy the pipeline ...